Enter inventor name

Churchville, PA, United States of America

James J Perkins

USPTO Granted Patents = 34 (Patent Applications = 10)

CIPO Patents = 1 (Patent Applications = 2)

EPO Patents = 9 (Patent Applications = 10)

Average Co-Inventor Count = 4.1

ph-index = 10

Forward Citations = 233(Granted Patents)

Location History:

Sanbornville, NH (US) (1981)
Philadelphia, PA (US) (1997)
Churchsville, PA (US) (2007 - 2010)
Chruchville, PA (US) (2016)
Sudan, NM (US) (2018)
Churchville, PA (US) (1998 - 2023)

Company Filing History:

Merck Sharp + Dohme Corp.

where one patent can have more than one assignee

Years Active: 1981-2025

Loading Chart...

34 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12344595 - 2-amino-n-phenyl-nicotinamides as NAV1.8 inhibitors (2025-07-01),

2. 12246008 - 4-amino or 4-alkoxy-substituted aryl sulfonamide compounds with selective activity in voltage-gated sodium channels (2025-03-11),

3. 12195445 - 2-amino-N-heteroaryl-nicotinamides as Na1.8 inhibitors (2025-01-14),

4. 11802122 - 2-oxoimidazolidine-4-carboxamides as NA1.8 inhibitors (2023-10-31),

5. 11377438 - 2-amino-n-heteroaryl-nicotinamides as Na1.8 inhibitors (2022-07-05),

6. 10072003 - Tetrahydronaphthyridine derivatives as mGluR2-negative allosteric modulators, compositions, and their use (2018-09-11),

7. D816587 - Toolbox (2018-05-01),

8. 9663506 - Quinoline carboxamide and quinoline carbonitrile derivatives as mGluR2-negative allosteric modulators, compositions, and their use (2017-05-30),

9. 9636337 - Quinoline carboxamide and quinoline carbonitrile derivatives as mGluR2-negative allosteric modulators, compositions, and their use (2017-05-02),

10. 9278960 - Quinoline carboxamide and quinoline carbonitrile derivatives as mGluR2-negative allosteric modulators, compositions, and their use (2016-03-08),

11. 8119681 - 2-[1-phenyl-5-hydroxy or methoxy-4alpha-methyl-hexahydrocyclopenta [ƒ]indazole-5-YL]ethyl phenyl derivatives as glucocorticoid receptor ligands (2012-02-21),

12. 7763659 - N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators (2010-07-27),

13. 7629367 - [object Object] (2009-12-08),

14. 7625920 - Fluorinated 4-azasteroid derivatives as androgen receptor modulators (2009-12-01),

15. 7605152 - 17-hydroxy-4-aza-androstan-3-ones as androgen receptor modulators (2009-10-20),

Title: James J Perkins: A Prolific Innovator in Pharmaceuticals

Introduction:

James J Perkins, a resident of Churchville, PA (US), is an esteemed inventor who has made significant contributions to the field of pharmaceuticals. With an impressive portfolio comprising 29 patents, Perkins has continually showcased his expertise in developing novel compounds for the treatment of various diseases. This article will delve into Perkins' latest patents, career highlights, notable collaborations, and his invaluable contributions to the industry.

Latest Patents:

Among Perkins' recent patents are two groundbreaking inventions aimed at inhibiting Na1.8 channel activity. The first patent involves 2-oxoimidazolidine-4-carboxamides as NA1.8 inhibitors. These compounds, denoted by the structural formula (I), and their pharmaceutically acceptable salts, exhibit potent inhibitory effects on Na1.8 channel activity. They hold immense potential in the treatment and management of pain disorders, cough disorders, acute itch disorders, and chronic itch disorders.

The second patent centers around 2-amino-n-heteroaryl-nicotinamides as Na1.8 inhibitors. Similarly, these compounds (also represented by the structural formula (I)) and their salts demonstrate exceptional inhibitory properties against Na1.8 channel activity. This innovation offers promising avenues for the prevention, management, and alleviation of diseases mediated by Na1.8 channel activity, including pain disorders, cough disorders, acute itch disorders, and chronic itch disorders.

Career Highlights:

Throughout his illustrious career, James J Perkins has made significant contributions while working with renowned pharmaceutical companies. Notably, he has held influential positions at Merck & Co., Inc. (commonly known as Merck) and Merck Sharp & Dohme Corporation. His expertise and innovative mindset have helped drive groundbreaking advancements in pharmaceutical research and development.

Collaborations:

Perkins has had the privilege of collaborating with esteemed professionals in the industry, including colleagues like Robert S Meissner and Mark E Duggan. These collaborations have fostered an environment of knowledge sharing and innovation, enabling Perkins to leverage collective expertise and achieve remarkable breakthroughs in his patented inventions.

Conclusion:

James J Perkins is a respected and accomplished inventor, renowned for his extensive patent portfolio, which highlights his significant contributions to the pharmaceutical industry. His recent patents involving Na1.8 inhibitors demonstrate his commitment to combating pain disorders, cough disorders, acute itch disorders, and chronic itch disorders. With a notable career at esteemed companies like Merck, Perkins has solidified his place as a leading figure in pharmaceutical innovation. Collaborations with fellow experts have further enhanced his achievements. Perkins' invaluable contributions continue to reshape the landscape of pharmaceutical research and offer hope for improved treatments for various medical conditions.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com